UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 894,217 shares of the company’s stock after selling 17,847 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.88% of Neurocrine Biosciences worth $103,032,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in shares of Neurocrine Biosciences by 0.8% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company’s stock worth $1,574,000 after buying an additional 90 shares during the period. Fifth Third Bancorp lifted its stake in shares of Neurocrine Biosciences by 14.7% during the second quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock worth $99,000 after buying an additional 92 shares during the period. Total Clarity Wealth Management Inc. lifted its stake in shares of Neurocrine Biosciences by 4.3% during the second quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company’s stock worth $335,000 after buying an additional 100 shares during the period. Commerce Bank lifted its stake in shares of Neurocrine Biosciences by 2.6% during the third quarter. Commerce Bank now owns 4,199 shares of the company’s stock worth $484,000 after buying an additional 108 shares during the period. Finally, Caprock Group LLC lifted its stake in shares of Neurocrine Biosciences by 7.0% during the second quarter. Caprock Group LLC now owns 1,669 shares of the company’s stock worth $230,000 after buying an additional 109 shares during the period. 92.59% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, September 16th. Piper Sandler upgraded shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $131.00 to $159.00 in a research note on Thursday, August 29th. Royal Bank of Canada decreased their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. BMO Capital Markets decreased their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Finally, Barclays decreased their target price on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Stock Up 0.1 %

NBIX stock opened at $126.75 on Monday. The stock has a market capitalization of $12.83 billion, a P/E ratio of 33.98 and a beta of 0.35. The firm has a 50-day simple moving average of $119.26 and a 200-day simple moving average of $131.48. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.